Sterling Pharma Solutions
David Molyneux has a diverse work experience in the pharmaceutical industry. David is currently the Vice President of Business Development at Sterling Pharma Solutions, a role they have held since June 2023. Prior to that, they were the Business Development Director at Sterling Pharma Solutions from September 2020 to June 2023.
Before joining Sterling Pharma Solutions, David worked at Alcami Corporation where they held the position of Senior Director of Global Sales and Business Development from September 2018 to September 2020. David also served as the Director of Sales and Business Development at Alcami Corporation from August 2017 to September 2018.
David started their career at Aesica Pharmaceuticals Ltd in 2012. During their time there, they held various roles including Business Development Director from February 2017 to August 2017, Business Development Manager from May 2015 to February 2017, Chemical Development Team Leader in April 2015, API Support Chemist from October 2013 to April 2015, and Development Chemist from August 2012 to October 2013.
Prior to joining Aesica Pharmaceuticals Ltd, David was a PhD student at Newcastle University from September 2009 to September 2012. David'sresearch focused on developing electro-synthetic routes to radiopharmaceuticals for medical imaging.
David's early career also includes a role as a Pilot Plant Operator at Aesica Pharmaceuticals Ltd in Cramlington, Northumberland, U.K. in 2009.
David Molyneux received their education at Newcastle University. From 2005 to 2009, they pursued their undergraduate studies and obtained an MChem (Hons.) degree in Chemistry with Medicinal Chemistry. Subsequently, David continued their academic journey at Newcastle University, undertaking a PhD program in Chemistry and Chemical Engineering from 2009 to 2012.
This person is not in any offices
Sterling Pharma Solutions
1 followers
Sterling Pharma Solutions has over 50 years' experience serving the global pharmaceutical industry. Our facilities are located in Cramlington and Newcastle Biosphere, UK; Deeside, Wales; Cork, Ireland, as well as North Carolina and Wisconsin in the US. Our state-of-the-art facilities, proprietary technologies and experienced people are among the best in the industry. We have a proven track record in the supply of chemistry and analytical services across the entire product lifecycle, from grams to tonnes, from pre-clinical to commercial supply. Our world-class safety and quality standards are globally recognised and demonstrated through successful MHRA and FDA inspections and CIA Gold Awards for Safety the last three consecutive years. We pride ourselves on our customer focus and service approach, offering flexible, tailored solutions to our customers. In addition, our North Carolina and Newcastle Biosphere facilities offer expert chemistry solutions for small volume batches or products in the early stages of clinical trials. Our Deeside, Wales facility provide bioconjugation development services and specialised in antibody drug conjugation (ADC) research and development. Find out more: www.sterlingpharmasolutions.com/sterling-facilities